Ultra Market Research | Viral Vectors and Plasmid DNA Manufacturing Market
Viral Vectors and Plasmid DNA Manufacturing Market
Report ID : 902
Category : Biotechnology,Global
No Of Pages : 100
Published on: December 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Viral Vectors and Plasmid DNA Manufacturing Market
Introduction
Viral Vectors & Plasmid DNA Manufacturing Market plays an integral role in gene therapy, vaccine development, and cell-based therapies. It uses viral vectors and plasmid DNA to deliver genetic material into cells for the treatment of various genetic disorders, cancers, and infectious diseases. Viral vectors such as adenoviruses, lentiviruses, and adeno-associated viruses are more commonly used for transferring genes into patient cells, and plasmid DNA has a critical role in the production of gene vaccines and therapeutic proteins. The market is highly growing due to the increase in genetic disorders, a rise in demand for cell and gene therapies, and developments in viral vector production technologies. The Viral Vectors & Plasmid DNA Manufacturing Market was valued at around USD 1.5 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15% from 2024 to 2030. North America is holding the largest market share at present, thanks to its robust healthcare infrastructure and significant investments in biotech research. This market's growth trajectory is on the way to growing application in therapeutic areas and expanding regulatory support.
Market Segmentation
Type of Product • Viral Vectors o Adenovirus o Lentivirus o Adeno-associated virus (AAV) o Others • Plasmid DNA o Linear Plasmid DNA o Circular Plasmid DNA o Others
Application • Gene Therapy o Inherited Disorders o Cancer Therapy o Others • Vaccine Development o DNA Vaccines o Viral Vector Vaccines o Others • Cell-based Therapy o CAR-T Therapy o Stem Cell Therapy o Others
End User • Pharmaceutical & Biotechnology Companies o Large Enterprises o Small and Medium Enterprises (SMEs) • Contract Research Organizations (CROs) o Vaccine Manufacturing o Clinical Trials Support • Academic Research Institutes o Research & Development (R&D) o Clinical Research
Production Scale • Small-scale Production o Pilot Production o Clinical-Grade Production • Large-scale Production o Commercial Production o Bulk Manufacturing
List of Market Players • Lonza Group (Switzerland) • WuXi AppTec (China) • Merck Group (Germany) • Cell and Gene Therapy Catapult (UK) • Biolife Solutions, Inc. (USA) • AGC Biologics (USA) • Viralgen Vector Core (Spain) • Oxford Biomedica (UK) • Cevipof Technologies (France) • Kite Pharma (USA) • Pharming Group (Netherlands) • Tocagen (USA) • Novartis Gene Therapies (USA) • Takara Bio (Japan) • Genscript Biotech Corporation (China)
Drivers
The key factors driving the growth of Viral Vectors & Plasmid DNA Manufacturing Market are an increase in gene therapies, mainly for genetic disorders, treatment of cancer, and rare diseases, where the demand is increasing for high-quality viral vectors and plasmid DNA. Increasing pipelines of gene-based vaccines and cell-based therapies also support the market's expansion. Bioprocessing technologies are also continuously improving, and efficiencies in the vector production processes have made it cheaper and scalable, hence vital to meet the needs of large-scale manufacturing of gene therapies. Moreover, governments and healthcare authorities worldwide are making significant investments in gene therapy infrastructure and providing regulatory support, thereby promoting the development of the sector. Market dynamics are also driven by rising investments in precision medicine research and healthcare spending. This shows a bright future for the viral vectors and plasmid DNA manufacturing market.
Restraints
Despite having strong growth prospects, the Viral Vectors & Plasmid DNA Manufacturing Market has several challenges to overcome. High production costs in the manufacturing of viral vectors and plasmids are one of the significant hurdles for small to medium-sized biotech firms. The production of viral vectors is quite complex and includes problems like scalability and quality control. Regulatory hurdles, along with lengthy approval processes for new gene therapies, also delay market entry and product commercialization. In addition, the potential for immune reactions in patients who are treated with viral vector-based therapies is a safety issue that may slow adoption. The lack of standardization in manufacturing processes and the scarcity of skilled labor in the field of gene therapy production also contribute to market constraints. These issues will have to be addressed to ensure long-term sustainable growth.
Opportunities
The Viral Vectors & Plasmid DNA Manufacturing Market presents numerous attractive opportunities to the stakeholders. The first key opportunity is that of increased genetic diseases and cancers; viral vector-based therapies may be a major area of hope. The second area of the development of DNA vaccines and mRNA-based therapies creates new openings for the viral vector and plasmid DNA market. Expansion of gene editing technologies such as CRISPR is another factor that will fuel growth. Moreover, with the rising interest in personalized medicine, there is a growing demand for scalable, cost-efficient manufacturing of viral vectors and plasmid DNA. Strategic collaborations between pharmaceutical companies, biotechs, and academic institutions will further accelerate innovation. These factors present numerous opportunities for businesses involved in this market to capitalize on.
Trends
The Viral Vectors & Plasmid DNA Manufacturing Market is undergoing several transformative trends. The most prominent trend is the automation of the manufacturing process, which enhances efficiency and reduces the likelihood of human error. This is increasingly adopted for scaling up production of gene therapies without increasing costs disproportionately. Another important trend is next-generation viral vectors, for example, optimized AAVs and lentiviruses, which show higher transfection efficiency and lower immunogenicity. Modular production systems are also advancing, which allows easier scalable production in a flexible, cost-effective manner. Cell-free expression systems are becoming popular in the production of plasmid DNA. They increase yield and minimize the risk of contamination. The frequency of ongoing collaborations and partnerships between leading pharmaceutical companies and contract manufacturing organizations (CMOs) is on the rise, thereby providing more opportunities for suppliers of viral vector and plasmid DNA. Finally, regulatory support for gene therapies is increasing and is a significant trend driving the growth of the market.
Approved Products and Pipeline
• Zolgensma (AAV vector-based therapy, approved for spinal muscular atrophy) • Kymriah (CAR-T cell therapy, uses lentiviral vector) • Luxturna (AAV-based gene therapy for retinal dystrophy) • Vaxzevria (AstraZeneca's COVID-19 vaccine, uses adenovirus vector) Pipeline Products: • Strimvelis (Gene therapy for ADA-SCID) • Yescarta (CAR-T therapy using lentivirus vector) • Valoctocogene roxaparvovec (Gene therapy for hemophilia A)
4. Global Viral Vectors and Plasmid DNA Manufacturing Market by Product Type
4.1 Viral Vectors
4.1.1 Market Size and Growth Rate (2024-2030)
4.1.1.1 Adenoviral Vectors
4.1.1.2 Adeno-associated Viral Vectors (AAV)
4.1.1.3 Lentiviral Vectors
4.1.1.4 Retroviral Vectors
4.1.1.5 Others
4.2 Plasmid DNA
4.2.1 Market Size and Growth Rate (2024-2030)
5. Global Viral Vectors and Plasmid DNA Manufacturing Market by Application
5.1 Gene Therapy
5.1.1 Market Size and Growth Rate (2024-2030)
5.1.1.1 Oncology
5.1.1.2 Genetic Disorders
5.1.1.3 Infectious Diseases
5.1.1.4 Others
5.2 Vaccine Development
5.2.1 Market Size and Growth Rate (2024-2030)
5.3 Protein Production
5.3.1 Market Size and Growth Rate (2024-2030)
5.4 Research & Development
5.4.1 Market Size and Growth Rate (2024-2030)
6. Global Viral Vectors and Plasmid DNA Manufacturing Market by End-User
6.1 Biotechnology & Pharmaceutical Companies
6.1.1 Market Size and Growth Rate (2024-2030)
6.2 Academic & Research Institutes
6.2.1 Market Size and Growth Rate (2024-2030)
6.3 Contract Research Organizations (CROs)
6.3.1 Market Size and Growth Rate (2024-2030)
6.4 Others
6.4.1 Market Size and Growth Rate (2024-2030)
7. Global Viral Vectors and Plasmid DNA Manufacturing Market by Region
7.1 North America
7.1.1 Market Size and Growth Rate (2024-2030)
7.1.2 United States
7.1.3 Canada
7.2 Europe
7.2.1 Market Size and Growth Rate (2024-2030)
7.2.2 Germany
7.2.3 France
7.2.4 United Kingdom
7.2.5 Rest of Europe
7.3 Asia Pacific
7.3.1 Market Size and Growth Rate (2024-2030)
7.3.2 China
7.3.3 Japan
7.3.4 India
7.3.5 Southeast Asia
7.3.6 Rest of Asia Pacific
7.4 Latin America
7.4.1 Market Size and Growth Rate (2024-2030)
7.4.2 Brazil
7.4.3 Mexico
7.4.4 Rest of Latin America
7.5 Middle East & Africa
7.5.1 Market Size and Growth Rate (2024-2030)
7.5.2 GCC
7.5.3 North Africa
7.5.4 South Africa
7.5.5 Rest of Middle East & Africa
8. Competitive Landscape
8.1 Company Profiles
8.1.1 [Company Name 1] • Business Overview • Product Portfolio • Strategic Developments • Financial Overview
8.1.2 [Company Name 2] • Business Overview • Product Portfolio • Strategic Developments • Financial Overview
8.1.3 [Company Name 3] • Business Overview • Product Portfolio • Strategic Developments • Financial Overview [Continue with profiles of other key market players]
9. List of Tables and Figures
Table 1: Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Product Type (2024-2030)
Table 2: Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Application (2024-2030)
Table 3: Global Viral Vectors and Plasmid DNA Manufacturing Market Size by End-User (2024-2030)
Table 4: Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region (2024-2030)
Figure 1: Global Viral Vectors and Plasmid DNA Manufacturing Market Size and Growth Rate (2024-2030)
Figure 2: Global Viral Vectors Market Share by Product Type (2024)
Figure 3: Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Application (2024-2030)
Figure 4: Global Viral Vectors and Plasmid DNA Manufacturing Market Size by End-User (2024-2030)
Figure 5: Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region (2024-2030)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Viral Vectors and Plasmid DNA Manufacturing Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Viral Vectors and Plasmid DNA Manufacturing Market for the past year and forecasts for the next six years. Viral Vectors and Plasmid DNA Manufacturing Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Viral Vectors and Plasmid DNA Manufacturing Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Viral Vectors and Plasmid DNA Manufacturing Market from different application industries in different regions.
Segmentation Service Type • Inpatient Services o General Medicine Cardiology Neurology Others o Surgical Services Orthopedic Surgeries Cardiovascular Surgeries o Critical Care ICU Services Emergency Services o Others • Outpatient Services o Diagnostic Services Imaging Services Laboratory Tests Others o Therapeutic Services Physiotherapy Rehabilitation o Preventive Care Vaccination Services Health Screenings o Others
Hospital Type • Public Hospitals o General Public Hospitals o Specialty Public Hospitals o Others • Private Hospitals o For-Profit Hospitals Multi-Specialty Hospitals Single Specialty Hospitals o Non-Profit Hospitals Charity-Based Hospitals o Others
End User • Individual Patients o Chronic Disease Patients o Acute Condition Patients • Corporate Clients o Occupational Health Services o Insurance Partnerships • Government Organizations o Military Hospitals o Public Health Initiatives • Others
Geography • North America o United States o Canada o Others • Europe o Germany o United Kingdom o Others • Asia-Pacific o China o India o Others • Latin America o Brazil o Mexico o Others • Middle East & Africa o GCC Countries o South Africa o Others